Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer

Jacobs T, Siziopikou K, Prioleau J, Raza S, Baum J, Hayes D, et al (1998) Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol 11: 259–264

Harris GC, Denley HE, Pinder SE, Lee AHS, Ellis IO, Elston CW, et al (2003) Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 27: 11–15

Mueller-Holzner E, Fink V, Frede T, Marth C (2001) Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 69: 13–19

Di Loreto C, Puglisi F, Rimondi G, Zuiani C, Anania G, Della Mea V, et al (1996) Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer 32A: 1693–1700

Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR (2002) A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 184: 322–324

King CR, Kraus MH, Aaronson SA (1983) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707–712

Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al (2001) Letrozole is more effective neodajuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659–2671

Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, et al (1999) Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, No-2, Mo). Wien Klin Wochenschr 111: 843–850

Bloom H, Richardson W (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–364

Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R (1990) Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061

Cohen J (1960) A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20: 37–46

Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Specificity of Hercep Test in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System. J Clin Oncol 17: 1983–1987

Kaya H, Ragazzini T, Aribal E, Guney I, Kotiloglu E (2001) Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma. Pathol Oncol Res 7: 279–283

Kaneko S, Gerasimova T, Butler WM, Cupples TE, Guerry PL, Greene GR, et al (2002) The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status. Exp Mol Pathol 73: 61–66

Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, et al (2001) HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079–1086

Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10: 91–98

Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974–1982

Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334–2356

Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16: 173–182

Mitchell MS, Press MF (1999) The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 26: 108–116

Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235: 10–26

Masood S, Bui MM (2002) Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microse Res Tech 59: 102–108

Wenzel C, Schmidinger M, Huber H (2001) Is there progress in chemotherapy for breast cancer? Wien Klin Wochenschr 113: 306–320

Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR (1999) c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84: 129–134

Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, et al (1996) Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105–3110

Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M (2000) Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP. Anticancer Res 20: 4373–4377

Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, et al (2002) Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8: 2835–2842

Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al (1994) The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335–341

Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714–2721

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26: 78–83